{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:33:59Z","timestamp":1793795639333,"version":"4.6.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Region Stockholm","award":["FoUI-1026094"],"award-info":[{"award-number":["FoUI-1026094"]}],"id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Region Stockholm","award":["FoUI-1002334"],"award-info":[{"award-number":["FoUI-1002334"]}],"id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-06351"],"award-info":[{"award-number":["2024-06351"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Eplerenone and spironolactone differ in pharmacological profile, but whether this translates into meaningful differences in clinical outcomes in heart failure (HF) remains uncertain. We compared the two agents in a registry-based new-user cohort with serial laboratory data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this observational cohort study, adults with a first HF diagnosis in Stockholm County (2005\u20132019) who were prescribed either spironolactone or eplerenone within 6 months were identified from linked Swedish registries with individual-level laboratory results. Follow-up was analysed under an intention-to-treat principle. Outcomes included all-cause mortality, HF hospitalization, kidney function decline, and hyperkalaemia. The main analysis used multivariable Cox regression. Several sensitivity analyses were performed, including propensity score matching. Of 75 565 patients with new-onset HF, 12 046 initiated a mineralocorticoid receptor antagonist (11 039 spironolactone; 1007 eplerenone). Eplerenone was associated with lower all-cause mortality (hazard ratio 0.78, 95% confidence interval 0.62\u20130.98), a lower risk of more than 50% decline in estimated glomerular filtration rate (eGFR) (0.69, 0.54\u20130.88), sustained eGFR below 30 mL\/min\/1.73 m2 (0.69, 0.49\u20130.95), a composite kidney outcome (0.71, 0.56\u20130.90), and hyperkalaemia of 5.5 mmol\/L or above (0.76, 0.60\u20130.96). The cause-specific hazard for HF hospitalization was higher with eplerenone (1.29, 1.11\u20131.51) but attenuated to 0.99 (0.87\u20131.12) when death was treated as a competing risk. Findings were robust across sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with spironolactone, eplerenone was associated with lower all-cause mortality and lower risks of kidney function decline and mild hyperkalaemia. These observational findings warrant confirmation in randomized comparisons.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag064","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:26:21Z","timestamp":1786879581000},"page":"501-511","source":"Crossref","is-referenced-by-count":1,"title":["Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8466-0038","authenticated-orcid":false,"given":"Karl","family":"W\u00e4rnberg","sequence":"first","affiliation":[{"name":"Department of Clinical Science, Danderyd Hospital, Karolinska Institutet , 182 88 Stockholm ,","place":["Sweden"]},{"name":"Department of Cardiology, Danderyd Hospital , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-6355","authenticated-orcid":false,"given":"Carl","family":"Hagg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Danderyd Hospital, Karolinska Institutet , 182 88 Stockholm ,","place":["Sweden"]},{"name":"Department of Cardiology, Danderyd Hospital , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9868-7047","authenticated-orcid":false,"given":"Karin","family":"Bergen","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Danderyd Hospital, Karolinska Institutet , 182 88 Stockholm ,","place":["Sweden"]},{"name":"Department of Nephrology, Danderyd Hospital , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-6987","authenticated-orcid":false,"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet , 171 76 Stockholm ,","place":["Sweden"]},{"name":"Department of Endocrinology, Karolinska University Hospital , Stockholm, 171 76 \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5789-8470","authenticated-orcid":false,"given":"Buster","family":"Mannheimer","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education at S\u00f6dersjukhuset, Karolinska Institutet , 118 83 Stockholm ,","place":["Sweden"]},{"name":"Department of Medicine, Section of Diabetes and Endocrinology, S\u00f6dersjukhuset , 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-7791","authenticated-orcid":false,"given":"Krister","family":"Lindmark","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Danderyd Hospital, Karolinska Institutet , 182 88 Stockholm ,","place":["Sweden"]},{"name":"Department of Cardiology, Danderyd Hospital , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026110318521024500_pvag064-B1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES)","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026110318521024500_pvag064-B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms (EMPHASIS-HF)","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026110318521024500_pvag064-B3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (EPHESUS)","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026110318521024500_pvag064-B4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction (TOPCAT)","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026110318521024500_pvag064-B5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026110318521024500_pvag064-B6","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026110318521024500_pvag064-B7","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026110318521024500_pvag064-B8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026110318521024500_pvag064-B9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/JPBS.JPBS_338_19","article-title":"Eplerenone: the multifaceted drug in cardiovascular pharmacology","volume":"12","author":"Pradhan","year":"2020","journal-title":"J Pharm Bioallied Sci"},{"key":"2026110318521024500_pvag064-B10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5455\/medarh.2023.77.105-111","article-title":"The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalisation and cardiovascular death in patients with chronic heart failure (HFrEF)","volume":"77","author":"Naser","year":"2023","journal-title":"Med Arch"},{"key":"2026110318521024500_pvag064-B11","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.hlc.2021.02.005","article-title":"The effects of spironolactone and eplerenone on left ventricular function using echocardiography in symptomatic patients with new-onset systolic heart failure: a comparative randomised controlled trial","volume":"30","author":"Nabati","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2026110318521024500_pvag064-B12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.mayocp.2024.11.009","article-title":"Eplerenone vs spironolactone and cardiac remodeling in heart failure with reduced ejection fraction: a meta-analysis","volume":"100","author":"Elshahat","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"2026110318521024500_pvag064-B13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2021.12.027","article-title":"Real world comparison of spironolactone and eplerenone in patients with heart failure","volume":"97","author":"Pardo-Mart\u00ednez","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2026110318521024500_pvag064-B14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ehjcvp\/pvad045","article-title":"Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study","volume":"9","author":"Larsson","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026110318521024500_pvag064-B15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12872-024-04103-7","article-title":"Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis","volume":"24","author":"Elshahat","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"2026110318521024500_pvag064-B16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.annepidem.2024.01.005","article-title":"Establishment and representativeness of the Stockholm Sodium Cohort: a laboratorial and pharmacoepidemiologic database covering 1.6 million individuals in the Stockholm County","volume":"91","author":"Issa","year":"2024","journal-title":"Ann Epidemiol"},{"key":"2026110318521024500_pvag064-B17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.kint.2020.07.013","article-title":"International consensus definitions of clinical trial outcomes for kidney failure: 2020","volume":"98","author":"Levin","year":"2020","journal-title":"Kidney Int"},{"key":"2026110318521024500_pvag064-B18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/00365513.2011.557086","article-title":"Revised equations for estimating glomerular filtration rate based on the Lund-Malm\u00f6 study cohort","volume":"71","author":"Bj\u00f6rk","year":"2011","journal-title":"Scand J Clin Lab Invest"},{"key":"2026110318521024500_pvag064-B19","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ehf2.12643","article-title":"Comparison of creatinine-based methods for estimating glomerular filtration rate in patients with heart failure","volume":"7","author":"Jonsson","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026110318521024500_pvag064-B20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1515\/cclm-2013-0741","article-title":"The revised Lund-Malm\u00f6 GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population","volume":"52","author":"Nyman","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2026110318521024500_pvag064-B21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/CLEP.S251710","article-title":"Identification of patients with new-onset heart failure and reduced ejection fraction in Danish administrative registers","volume":"12","author":"Madelaire","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2026110318521024500_pvag064-B22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/ehjcvp\/pvag030","article-title":"Initiation of eplerenone vs spironolactone and all-cause mortality in HFrEF: linked database study","volume":"12","author":"Svanstr\u00f6m","year":"2026","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026110318521024500_pvag064-B23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ejhf.3230","article-title":"Cause-specific death in heart failure across the ejection fraction spectrum: a comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry","volume":"26","author":"Settergren","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026110318521024500_pvag064-B24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag064\/71018104\/pvag064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/7\/501\/71018104\/pvag064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/7\/501\/71018104\/pvag064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:52:20Z","timestamp":1793749940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/7\/501\/8789862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag064","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,10]]}}}